Novartis AG ADR (NVS)vsProtara Therapeutics Inc (TARA)

NVS

Novartis AG ADR

NYSE

$158.83

-0.25%

HEALTHCARE · Cap: $290.96B

TARA

Protara Therapeutics Inc

NASDAQ

$4.03

+5.77%

HEALTHCARE · Cap: $230.44M

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

TARA

Avoid

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.0

Piotroski: 1/9Altman Z: 6.95

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-70.9%)

Margin of Safety

-70.9%

Fair Value

$92.73

Current Price

$158.83

$66.10 premium

UndervaluedFair: $92.73Overvalued

Intrinsic value data unavailable for TARA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability

22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality

$5.57B8/10

Generating 5.6B in free cash flow

TARA3 strengths · Avg: 10.0/10

Price/BookValuation

1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth

0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth

6.9510/10

Safe zone — low bankruptcy risk

Areas to Watch

NVS4 concerns · Avg: 3.3/10

Revenue GrowthGrowth

0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.183/10

Elevated debt levels

PEG RatioValuation

4.152/10

Expensive relative to growth rate

TARA4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$230.44M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bull Case : TARA

The strongest argument for TARA centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : TARA

The primary concerns for TARA are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

TARA carries more volatility with a beta of 1.48 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 29/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.

Visit Website →

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs MRK NVS vs AZN TARA vs LLY TARA vs JNJ TARA vs ABBV TARA vs MRK TARA vs AZN

Want to dig deeper into these stocks?

Full NVS Analysis →Full TARA Analysis →